Literature DB >> 21489029

End-stage renal disease predicts complications in pacemaker and ICD implants.

Christine Tompkins1, Rhondalyn McLean, Alan Cheng, Jeffrey A Brinker, Joseph E Marine, Saman Nazarian, David D Spragg, Sunil Sinha, Henry Halperin, Gordon F Tomaselli, Ronald D Berger, Hugh Calkins, Charles A Henrikson.   

Abstract

INTRODUCTION: Patients with chronic kidney disease (CKD) have increased morbidity following invasive procedures. We hypothesized that patients with CKD have higher complication rates following device implantation than patients with normal renal function.
METHODS: We reviewed the medical records of patients undergoing ICD or pacemaker implantation from August 2004 to August 2007. The estimated glomerular filtration rate (GFR) was calculated using the Cockroft-Gault equation. Those with GFR ≥ 90 cc/min served as controls. The remainder was grouped according to American Kidney Foundation stages of CKD. Bleeding complications were defined as need for pocket exploration or blood transfusion; cardiac tamponade; or hematoma requiring pressure dressing, change in medications or prolonged hospitalization. Infection was defined as infection of the pocket or lead system, or development of bacteremia/sepsis within 60 days.
RESULTS: There were 82 bleeding complications (5.7%) and 7 infections (0.5%) temporally related to device implantation in 1,440 patients. End-stage renal disease (ESRD), defined as GFR < 15 mL/min or need for dialysis, was identified in 32 patients. Infection rates were significantly higher in patients with ESRD versus controls (12.5% vs 0.2%; P < 0.0001). A significant increase in bleeding complications was observed in ESRD versus controls (21.9% vs 3.2%, respectively; P<0.0001). Bleeding complications were considerably greater than controls in moderate (GFR 30-59 mL/min) and severe (GFR 15-29 mL/min) CKD (7.4% and 9.8% vs 3.2%, respectively; P < 0.005).
CONCLUSION: ESRD markedly increases bleeding and device-related infections. The risk of both complications parallels the severity of CKD. Further research is needed to reduce adverse outcomes in this high-risk population.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21489029     DOI: 10.1111/j.1540-8167.2011.02066.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  31 in total

1.  Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease.

Authors:  Nisha Bansal; Adam Szpiro; Kristi Reynolds; David H Smith; David J Magid; Jerry H Gurwitz; Frederick Masoudi; Robert T Greenlee; Grace H Tabada; Sue Hee Sung; Ashveena Dighe; Alan S Go
Journal:  JAMA Intern Med       Date:  2018-03-01       Impact factor: 21.873

2.  Do implantable defibrillators help patients with CKD?

Authors:  David M Charytan; Matthew R Reynolds
Journal:  Am J Kidney Dis       Date:  2014-07       Impact factor: 8.860

3.  Shades of grey: the conundrum of implantable defibrillators in individuals with advanced CKD.

Authors:  Aisha Khattak; David M Charytan
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-25       Impact factor: 8.237

Review 4.  The subcutaneous ICD-current evidence and challenges.

Authors:  Kiran Haresh Kumar Patel; Pier D Lambiase
Journal:  Cardiovasc Diagn Ther       Date:  2014-12

Review 5.  Outcomes of ICDs and CRTs in patients with chronic kidney disease: a meta-analysis of 21,000 patients.

Authors:  Mohammed Shurrab; Dennis T Ko; Yazan Zayed; Sankar D Navaneethan; Nour Yadak; Abeer Yaseen; Anna Kaoutskaia; Waad Qamhia; Zakaria Hamdan; Saleem Haj-Yahia; Douglas S Lee; David Newman; Jeff S Healey; Paula Harvey; Eugene Crystal
Journal:  J Interv Card Electrophysiol       Date:  2018-07-30       Impact factor: 1.900

Review 6.  Prevention of sudden cardiac death in patients with chronic kidney disease: risk and benefits of the implantable cardioverter defibrillator.

Authors:  Jana M Hoffmeister; N A Mark Estes; Ann C Garlitski
Journal:  J Interv Card Electrophysiol       Date:  2012-08-07       Impact factor: 1.900

7.  Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators.

Authors:  Nisha Bansal; Adam Szpiro; Frederick Masoudi; Robert T Greenlee; David H Smith; David J Magid; Jerry H Gurwitz; Kristi Reynolds; Grace H Tabada; Sue Hee Sung; Ashveena Dighe; Andrea Cassidy-Bushrow; Romel Garcia-Montilla; Stephen Hammill; John Hayes; Alan Kadish; Param Sharma; Paul Varosy; Humberto Vidaillet; Alan S Go
Journal:  Heart       Date:  2016-10-14       Impact factor: 5.994

8.  Clinical presentation and outcomes of cardiovascular implantable electronic device infections in hemodialysis patients.

Authors:  LaTonya J Hickson; Janelle Y Gooden; Katherine Y Le; Larry M Baddour; Paul A Friedman; David L Hayes; Walter R Wilson; James M Steckelberg; M Rizwan Sohail
Journal:  Am J Kidney Dis       Date:  2014-01-03       Impact factor: 8.860

9.  Influence of renal function on mortality and ventricular arrhythmias in patients undergoing first implantable cardioverter-defibrillator generator replacement.

Authors:  Jonathan W Waks; Angela Y Higgins; Murray A Mittleman; Alfred E Buxton
Journal:  J Cardiovasc Electrophysiol       Date:  2015-01-07

10.  New Insights into Predictors of Cardiac Implantable Electronic Device Infection.

Authors:  Hossein Sadeghi; Abolfath Alizadehdiz; Amirfarjam Fazelifar; Zahra Emkanjoo; Majid Haghjoo
Journal:  Tex Heart Inst J       Date:  2018-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.